Founded in 1819, Cravath, Swaine & Moore LLP is widely recognized as one of the preeminent law firms in the world. Each of its practices is highly regarded and its lawyers are recognized for their commitment to the representation of their clients' interests in the United States and internationally.
Cravath represents some of the largest and most highly regarded companies in the life sciences industry on a variety of corporate and litigation matters. We have played a leading role in critical and complex transactions and cases that have defined the life sciences industry, including handling one of the first suits to proceed under the Biologics Price Competition and Innovation Act, in which we represented Amgen in a lawsuit arising from its anticipated introduction of the first biosimilar to AbbVie's biologic drug, Humira®.
Our attorneys bring to the table an understanding of the life sciences industry coupled with extensive corporate and litigation experience handling high-level matters in other areas, giving us both the depth and breadth of expertise to creatively and effectively solve problems affecting all aspects of our clients' businesses.
The Firm represents pharmaceutical, biotechnology, healthcare services and medical device companies in significant intellectual property and antitrust litigation; complex shareholder derivative and securities suits; breach of contract and licensing disputes; and arbitrations. We also handle government and internal investigations; regulatory enforcement; and compliance matters for life sciences clients, as well as regulatory clearance and antitrust advice relating to mergers and acquisitions.
On the corporate side, we advise life sciences companies and their boards of directors in mergers and acquisitions; corporate governance matters, including defense against activist hedge funds; capital markets offerings and banking and credit transactions; financial restructuring and reorganization; tax; and executive compensation and benefits matters. Cravath's environmental lawyers work with its life sciences clients on acquisition and disposition strategies as well as financings and advise on the challenges and opportunities associated with environmental, social and governance ("ESG") issues, sustainability concerns and climate change. Our corporate IP lawyers advise on acquisitions and divestitures; multiparty joint ventures and strategic investments; licensing agreements; and portfolio development and exploitation.
Cravath's clients in this area have included: Abiomed, Actelion, Akorn, Amgen, Chemed, Insys Therapeutics, Johnson & Johnson, Medinol, Merck & Co., Mylan Laboratories, Novartis Pharmaceuticals, OrbusNeich, RedHill Biopharma, Roivant Sciences and Vitaworks.
2020 LMG Life Sciences Stars: